Medicare Add-On Payments For Praxbind, Andexanet Under Consideration
This article was originally published in The Pink Sheet Daily
Executive Summary
Although few drugs have ever gotten the new technology designation, the two antidotes for excessive bleeding caused by anticoagulant treatments seem to have a good chance of being awarded added payments by CMS.
You may also be interested in...
Six Weeks Too Late? Praxbind Gets 2017 Medicare Boost But Not AndexXa
User fee date for Portola's anticoagulant reversal agent is near, but not soon enough for Medicare's new technology payments in 2017 – while Boehringer's Praxbind gets in in time; BTG's Vistogard also gains the extra payments.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.